Delecção 1p36 – A Síndrome Não Explica Tudo…

Introdução: A criança com co-morbilidade grave é um premente desafio diagnóstico, cujo sucesso depende de uma abordagem multi-disciplinar. A síndrome de delecção 1p36, microdelecção subtelomérica de apresentação clínica pleiotrópica e multissistémica, pode incluir atraso do desenvolvimento psicomotor, alterações cardíacas, neurológicas e gastrointestinais. Caso Clínico: Filha única de pais não consanguíneos, PNV sem vacinação anti pneumocócica, com múltiplos internamentos: choque cardiogénico com miocardiopatia dilatada (3M), sépsis a S. aureus e Streptococcus do grupo G (5M) e várias intercorrencias infecciosas (varicela, gastrenterite, bronquiolite, febre sem foco). Aos 22 meses é reinternada por choque séptico com falência multi-orgânica por Streptococcus pneumoniae (serotipo 23-F), complicada de osteomielite dos ossos do antebraço e abcesso abdominal com necessidade de cirurgia. Pelos antecedentes e gravidade desta sépsis pneumocócica investigou-se eventual imunodeficiência identificando-se asplenia, confirmada por corpos de Howell-Jolly, TC abdominal e laparotomia. Retrospectivamente, para além da miocardiopatia havia má progressão ponderal com dificuldades alimentares, atraso global do desenvolvimento psicomotor, dermatose eczematosa grave e hipereosinofilia (2.410-5.680/uL), investigada por Genética, Infecciologia e Doenças Metabólicas. O cariotipo revelou monossomia da região distal ao locus 1p36 – delecção 1p36. Cintigrafia com MIBG sem evidência de neuroblastoma (risco aumentado pela síndrome). O estudo metabólico foi negativo, à excepção de défice de L-carnitina, pelo que mantem suplementos estando em curso estudo molecular de CPT2 – gene associado a défice de carnitina, na localização 1p32. Quanto à hipereosinofilia, verificou-se IgE aumentada e biopsia óssea normal pelo que iniciou prednisolona 2mg/Kg/dia com resposta favorável, estando estudo molecular específico em curso. Discussão: No fenótipo da síndrome enquadram-se o atraso global do desenvolvimento, a miocardiopatia e dificuldades alimentares. A asplenia, hipereosinofilia e dermatose eczematosa graves, não associadas a esta síndrome e de etiologia ainda a esclarecer podem-se integrar eventualmente na delecção terminal do cromossoma 1. As alterações no cariotipo carecem ainda de caracterização do ponto de quebra centromérico através de array-CGH, teste com maior especificidade para avaliar a tradução clínica dos efeitos individuais e combinados dos genes envolvidos.

Differential Internalization of Amphotericin B - Conjugated Nanoparticles in Human Cells and the Expression of Heat Shock Protein 70

Although a variety of nanoparticles (NPs) functionalized with amphotericin B, an antifungal agent widely used in the clinic, have been studied in the last years their cytotoxicity profile remains elusive. Here we show that human endothelial cells take up high amounts of silica nanoparticles (SNPs) conjugated with amphotericin B (AmB) (SNP-AmB) (65.4 12.4 pg of Si per cell) through macropinocytosis while human fibroblasts internalize relatively low amounts (2.3 0.4 pg of Si per cell) because of their low capacity for macropinocytosis. We further show that concentrations of SNP-AmB and SNP up to 400 mg/mL do not substantially affect fibroblasts. In contrast, endothelial cells are sensitive to low concentrations of NPs (above 10 mg/mL), in particular to SNP-AmB. This is because of their capacity to internalize high concentration of NPs and high sensitivity of their membrane to the effects of AmB. Low-moderate concentrations of SNP-AmB (up to 100 mg/mL) induce the production of reactive oxygen species (ROS), LDH release, high expression of pro-inflammatory cytokines and chemokines (IL-8, IL-6, G-CSF, CCL4, IL-1b and CSF2) and high expression of heat shock proteins (HSPs) at gene and protein levels. High concentrations of SNP-AmB (above 100 ug/mL) disturb membrane integrity and kill rapidly human cells(60% after 5 h). This effect is higher in SNP-AmB than in SNP.

Prostate Cancer: The Role of Multiparametric Magnetic Resonance Imaging

Multiparametric Magnetic Resonance Imaging has been increasingly used for detection, localization and staging of prostate cancer over the last years. It combines high-resolution T2 Weighted-Imaging and at least two functional techniques, which include Dynamic Contrast–Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and Magnetic Resonance Imaging Spectroscopy. Although the combined use of a pelvic phased-array and an Endorectal Coil is considered the state-of-the-art for Magnetic Resonance Imaging evaluation of prostate cancer, Endorectal Coil is only absolute mandatory for Magnetic Resonance Imaging Spectroscopy at 1.5 T. Sensitivity and specificity levels in cancer detection and localization have been improving with functional technique implementation, compared to T2 Weighted-Imaging alone. It has been particularly useful to evaluate patients with abnormal PSA and negative biopsy. Moreover, the information added by the functional techniques may correlate to cancer aggressiveness and therefore be useful to select patients for focal radiotherapy, prostate sparing surgery, focal ablative therapy and active surveillance. However, more studies are needed to compare the functional techniques and understand the advantages and disadvantages of each one. This article reviews the basic principles of prostatic mp-Magnetic Resonance Imaging, emphasizing its role on detection, staging and active surveillance of prostate cancer.

Gene Expression Profiling and Association Studies Implicate the Neuregulin Signaling Pathway in Behçet's Disease Susceptibility

Behçet's disease (BD) is a complex disease with genetic and environmental risk factors implicated in its etiology; however, its pathophysiology is poorly understood. To decipher BD's genetic underpinnings, we combined gene expression profiling with pathway analysis and association studies. We compared the gene expression profiles in peripheral blood mononuclear cells (PBMCs) of 15 patients and 14 matched controls using Affymetrix microarrays and found that the neuregulin signaling pathway was over-represented among the differentially expressed genes. The Epiregulin (EREG), Amphiregulin (AREG), and Neuregulin-1 (NRG1) genes of this pathway stand out as they are also among the top differentially expressed genes. Twelve haplotype tagging SNPs at the EREG-AREG locus and 15 SNPs in NRG1 found associated in at least one published BD genome-wide association study were tested for association with BD in a dataset of 976 Iranian patients and 839 controls. We found a novel association with BD for the rs6845297 SNP located downstream of EREG, and replicated three associations at NRG1 (rs4489285, rs383632, and rs1462891). Multifactor dimensionality reduction analysis indicated the existence of epistatic interactions between EREG and NRG1 variants. EREG-AREG and NRG1, which are members of the epidermal growth factor (EGF) family, seem to modulate BD susceptibility through main effects and gene–gene interactions. These association findings support a role for the EGF/ErbB signaling pathway inBD pathogenesis that warrants further investigation and highlight the importance of combining genetic and genomic approaches to dissect the genetic architecture of complex diseases.

Genetic Screening of LCA in Belgium: Predominance of CEP290 and Identification of Potential Modifier Alleles in AHI1 of CEP290-Related Phenotypes

Leber Congenital Amaurosis (LCA), the most severe inherited retinal dystrophy, is genetically heterogeneous, with 14 genes accounting for 70% of patients. Here, 91 LCA probands underwent LCA chip analysis and subsequent sequencing of 6 genes (CEP290, CRB1, RPE65, GUCY2D, AIPL1and CRX), revealing mutations in 69% of the cohort, with major involvement of CEP290 (30%). In addition, 11 patients with early-onset retinal dystrophy (EORD) and 13 patients with Senior-Loken syndrome (SLS), LCA-Joubert syndrome (LCA-JS) or cerebello-oculo-renal syndrome (CORS) were included. Exhaustive re-inspection of the overall phenotypes in our LCA cohort revealed novel insights mainly regarding the CEP290-related phenotype. The AHI1 gene was screened as a candidate modifier gene in three patients with the same CEP290 genotype but different neurological involvement. Interestingly, a heterozygous novel AHI1 mutation, p.Asn811Lys, was found in the most severely affected patient. Moreover, AHI1 screening in five other patients with CEP290-related disease and neurological involvement revealed a second novel missense variant, p.His758Pro, in one LCA patient with mild mental retardation and autism. These two AHI1 mutations might thus represent neurological modifiers of CEP290-related disease.